


PTO/3B/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	10/022,862
Filing Date	12-13-2001
Confirmation Number	4101
First Named Inventor	M. Obukowicz
Group Art Unit	101 1651
Attorney Docket No.	3475/1A/US (PHA 4140.7)

Sheet

9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
MM	1	4,613,591	B1	Aburada et al.	09-23-1986
	2	5,380,738	B1	Norman et al.	01-10-1995
	3	5,344,991	B1	Reitz et al.	09-06-1994
	4	5,393,790	B1	Reitz et al.	02-28-1995
	5	5,466,823	B1	Talley et al.	11-14-1995
	6	5,521,207	B1	Graneto	05-28-1996
	7	5,633,272	B1	Talley et al.	05-27-1997
	8	5,753,688	B1	Talley et al.	05-19-1998
	9	5,760,068	B1	Talley et al.	06-02-1998
	10	5,811,425	B1	Woods et al.	09-22-1998
	11	5,932,598	B1	Talley et al.	08-03-1999

04/19/2002 SSANDARA 00000031 10022862

01 FC:126

180.00 OP

Examiner Signature		Date Considered	9/23/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST: 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/022,862
			Filing Date	12-13-2001
			Confirmation Number	4101
			First Named Inventor	M. Obukowicz
			Group Art Unit	1614
Sheet	2	OF 9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
<i>MM</i>	12	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	13	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
	14	WO	00/74696	A1	Oxford Natural Products PLC	12-14-2000	
	15	JP	4208222		Tsumura & co.	07-29-1992	X
	16	JP	4005237	A	Nonogawa Shoji:kk (abstract)	01-09-1992	
	17	JP	2000236835		Seika et al. (abstract)	09-05-2000	
	18	EP	248215	B1	Popp et al.	12-09-1987	
	19	WO	94/12165	A	Wellcome et al.	06-09-1994	
	20	WO	94/14780	A	Wellcome et al.	07-07-1994	
	21	WO	93/13055	A	Glaxo Wellcome Inc.	07-08-1993	
	22	WO	95/11231	A	Bergmanis et al.	04-27-1995	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>9/23/02</i>
-----------------------	--------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/022,862	
		Filing Date	12-13-2001	
		Confirmation Number	4101	
		First Named Inventor	M. Obukowicz	
		Group Art Unit	1614	
Sheet	3	9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
M/M	23	KASE, et al., Mechanisms by which Hange-shashin-to reduces prostaglandin E2 levels, <i>Biol. Pharm. Bull.</i> , 1998, pp. 1277-1281, Vol. 21, No. 12.	
	24	RINGBOM et al., Ursolic Acid from <i>Plantago major</i> , a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin Biosynthesis, <i>J. Nat. Prod.</i> , 1998, pp. 1212-1215, Vol. 61, No. 10.	
	25	PENNISI, E., Building a Better Aspirin, <i>Science</i> , 1998, pp. 1191-1192, Vol. 280.	
	26	RESCH et al., 5-Lipoxygenase and Cyclooxygenase-1 Inhibitory Active Compounds from <i>Atractylodes Lancea</i> , <i>J. Nat. Prod.</i> , 1998, pp. 347-350, Vol. 61.	
	27	RUBIN, et al., Pharmacokinetics, Safety, and Ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase, <i>Agents Actions Suppl.</i> , 1991, pp. 103-116, Vol. 35. (abstract only)	
	28	CARTER, et al., 5-Lipoxygenase inhibitory activity of Zileuton, <i>J. Pharmacol. & Exp. Ther.</i> , 1991, pp. 929-937, Vol. 256, Vol. 3.	
	29	SUBBARAMAIAH et al., Resveratrol Inhibits the Expression of Cyclooxygenase-2 in Human Mammary and Oral Epithelial Cells, <i>Pharmaceutical Biology</i> , 1998, pp. 35-43, Vol. 36.	
	30	BINGOL et al., A Review of Terrestrial Plants and Marine Organisms Having Antiinflammatory Activity. <i>International Journal of Pharmacognosy</i> , 1995, pp. 81-97, Vol. 33, No. 2.	
	31	MARNETT et al., Arachidonic Acid Oxygenation by COX-1 and COX-2, <i>The Journal of Biological Chemistry</i> , 1999, pp. 22903-22906, Vol. 274, No. 33.	
	32	KALGUTKAR et al., Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2, <i>Science</i> , 1998, pp. 1268-1270, Vol. 280.	
	33	KALGUTKAR, et al., Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective Cox-2 Inhibitors, <i>PNAS</i> , 2000, pp. 925-930, Vol. 97, No. 2.	

Examiner Signature	<i>[Signature]</i>	Date Considered	9/23/02
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/022,862	
		Filing Date	12-13-2001	
		Confirmation Number	4101	
		First Named Inventor	M. Obukowicz	
		Group Art Unit	1614	
Sheet	4	9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

34	BATRISTINI et al., COX-1 and COX-2: Toward the development of More selective NSAIDs, <i>DN&P</i> , 1994, pp. 50-512, Vol. 7, No. 8.
35	MITCHELL et al., "Cyclooxygenase-2: Regulation and Relevance in Inflammation." <i>Biochemical Pharmacology</i> , 1995, pp. 1535-1542, Vol. 50, No. 10.
36	WHITEHOUSE et al., "Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?" <i>Inflammopharmacology</i> , 1999, pp. 89-105, Vol. 7, No. 2.
37	DEWITT et al., "The Differential Susceptibility of Prostaglandin Endoperoxide H Synthases-1 and -2 to Nonsteroidal Anti-Inflammatory Drugs: Aspirin Derivatives as Selective Inhibitors." <i>Med Chem Res</i> , 1995, pp. 325-343, Vol. 5.
38	DUKE, J., "Clippings from my COX Box." <i>Journal of Medicinal Food</i> , 1998/1999, pp. 293-298, Vol. 1, No. 4.
39	MCADAM et al., "Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of Cox-2." <i>Proc. Nat. Acad. Sci. USA</i> , 1999, pp. 272-277, Vol. 96.
40	O'NEILL et al., "Overexpression of Human Prostaglandin G/H Synthase-1 and -2 by Recombinant Vaccinia Virus: Inhibition by Nonsteroidal Anti-Inflammatory Drugs and Biosynthesis of 15-Hydroxyeicosatetraenoic Acid." <i>Mole. Pharmacol</i> , 1994, pp. 245-254, Vol. 45.
41	AUERBACH et al., "A Spectrophotometric Microtiter-Based Assay for the Detection of Hydroperoxy Derivatives of Linoleic Acid." <i>Anal. Biochem</i> , 1992, pp. 375-380, Vol. 201.
42	NOWLIN et al., "A Novel Cyclic Pentapeptide Inhibits $\alpha 4\beta 1$ and $\alpha 5\beta 1$ Integrin-mediated cell Adhesion." <i>J. Biol. Chem</i> , 1993, pp. 20352-20359, Vol. 268.
43	STOLTENBORG et al., "A fluorescent cellular adhesion assay using insect cell produced human VCAM1", <i>J. Immunological Methods</i> , 1994, pp. 59-68, Vol. 175.
44	WELKER et al., "Glucocorticoid-Induced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells", <i>International Arch of Allergy and Immunology</i> , 1996, pp. 110-115, Vol. 109.
45	KOIZUMI et al., "Inhibitors of IL-2 Production and IL-2 Receptor Expression in Human Leukemic T-Cell Line, Jurkat," <i>Cellular Immunology</i> , 1986, pp. 469-475, Vol. 103.
Examiner Signature	Date Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/022,862
				Filing Date	12-13-2001
				Confirmation Number	4101
				First Named Inventor	M. Obukowicz
				Group Art Unit	1614
Sheet	5	OF	9	Attorney Docket No.	3475/1A/US (PHA 4140.7)


 APR 22 2002
 TECH CENTER 1600/2B00

	46	COHEN et al., "Cytokine Function" Am. J. Clin. Pathol., 1996, pp. 589-598, Vol. 105., No. 5.	
	47	HENDERSON et al., "Therapeutic potential of cytokine manipulation", TIPS, 1992, pp. 145-152, Vol. 13.	
	48	ELIAS et al., "Synergistic Stimulation of Fibroblast Prostaglandin Production by Recombinant Interleukin 1 and Tumor Necrosis Factor", J. Immunol., 1987, pp. 3812-3816, Vol. 138.	
	49	LENARDO et al., "NF-kB: A Pleiotrophic Mediator of Inducible and Tissue-Specific Gene Control", Cell, 1989, pp. 227-229, Vol. 58.	
	50	MALOFF et al., "Development of an RIA-based primary screen for IL-1 antagonists" Clin. Chim. Acta., 1988, pp. 73-78, Vol. 180.	
	51	KARTTUMEN et al., "Measurement of ligand-induced activation in single viable T cells using the <i>lacZ</i> reporter gene", Proc. Nat'l. Acad. Sci, 1991, pp. 3972-3976, Vol. 88.	
	52	EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation", Science, 1989, pp. 1617-1620, Vol. 246.	
	53	CHANG et al., "The Influence of Chinese Traditional Medicine on the Production and Activity of Interleukin 1", Chinese J. Microbiol. Immunol., 1993, pp. 15-24, Vol. 26.	
	54	MIN, K.R. et al. "(-)-Epiarznelechin: Cyclooxygenase-1 Inhibitor and Anti-Inflammatory Agency from Aerial Parts of <i>Celastrus orbiculatus</i> ", Planta Med., 1999, pp. 460-462, Vol. 65.	
	55	LEE et al. "a-Viniferin: A Prostaglandin H2 Synthase Inhibitor from Root of <i>Carex humilis</i> ", Planta Med., 1998, pp. 195-290, Vol. 64.	
	56	NOREEN et al., "Flavan-3-ols isolated from Some Medicinal Plants Inhibiting COX-1 and COX-2 Catalysed Prostaglandin Biosynthesis", 1998, pp. 520-524, Vol. 64.	
	58	DANZ et al., "Identification and Isolation of the Cyclooxygenase-2 Inhibitory Principle in <i>Isatis tinctoria</i> ", Planta Med. 67, pp. 411-416, Vol. 67.	
	59	TAYLOR et al., "COX-1 inhibitory activity in extracts from <i>Eucomis</i> L'Herit. species", J. Ethnopharmacol., 2001, pp. 257-265, Vol. 76, Nos. 2-3.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/022,862
			Filing Date	12-13-2001
			Confirmation Number	4101
			First Named Inventor	M. Obukowicz
			Group Art Unit	1614
Sheet		9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

60	CHOU et al., "The inhibitory effect of common traditional anti-rheumatic herb formulas on prostaglandin E and interleukin 2 in vitro: A comparative study with <i>Tripterygium wilfordii</i> ", J. Ethnopharmacol., 1998, pp. 167-171, Vol. 62, No. 2.	
61	ZSCHOCKE et al., "5-Lipoxygenase and Cyclooxygenase Inhibitory Active Constituents from Qianghuo (<i>Notopterygium incisum</i>)", Planta Med., 1997, pp. 203-206, Vol. 63.	
62	KIM et al., "Effects of naturally- occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea pigs", Prostaglandins Leukot. Essent. Fatty Acids, 1998 58(1); pp. 17-24.	
63	TUNON et al., "Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis", J. Ethnopharmacol 48, 1995, pp. 61-76.	
64	YOU et al., "Inhibition of Cyclooxygenase/Lipoxygenase from Human Platelets by Polyhydroxylated/Methoxylated Flavonoids Isolated from Medicinal Plants", Arch. Pharm. Res. 1999, pp. 18-24, Vol. 22, No. 1.	
65	SEGURA et al., "Anti-Inflammatory Activity of Dichloromethane Extract of <i>Heterotheca inuloids in Vivo and in Vitro</i> ", Planta Med., 2000, pp. 553-555, Vol. 66.	
66	DUNSTAN et al., " Evaluation of some Samoan and Peruvian medicinal plants by prostaglandin biosynthesis and rat ear oedema assays", J. Ethnopharmacol, 1997, pp. 35-56, Vol. 57, No. 1.	
67	ABAD et al., "The Activity of Flavonoids Extracted from <i>Tanacetum microphyllum</i> DC. (Compositae) on Soybean Lipoxygenase and Prostaglandin Synthetase, Gen. Pharmacolm 1995, pp. 815-819, Vol. 26, No. 4.	
68	ABAD et al. , "Anti-inflammatory Activity of Hydroxyachillin, a Sesquiterpene Lactone from <i>Tanacetum microphyllum</i> ", Planta Med., 1994, pp. 228-231, Vol. 60.	
69	WANG et al., "Antioxidant and Antiinflammatory Activities of Anthocyanins and Their Aglycon, Cyanidin, from Tart Cherries", J. Nat. Prod., 1999, pp. 294- 296, Vol. 62, No. 2.	
70	RESCH et al., "Further Phenols and Polyacetylenes from the Rhizomes of <i>Atractylodes lancea</i> and their Anti-Inflammatory Activity", Planta Med., 2001, pp. 437-442. Vol. 67.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/022,862
		Filing Date	12-13-2001
		Confirmation Number	4101
		First Named Inventor	M. Obukowicz
		Group Art Unit	1614
Sheet	9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

71	JAGER et al., "Screening of Zulu medicinal plants for prostaglandin synthesis inhibitors", J. Ethnopharmacol, 1996, pp. 95-100, Vol. 52, No. 2.
72	RINGBOM et al., "COX-2 Inhibitory Effects of Naturally Occurring and Modified Fatty Acids", J. Nat. Prod., 2001, pp., 745-749, Vol. 64, No. 6.
73	NOREEN et al., "Development of a Radiochemical Cyclooxygenase-1 and -2 in Vitro Assay for Identification of Natural Products as Inhibitors of Prostaglandin Biosynthesis", J. Nat. Prod., 1998, Vol. 61, No. 1.
74	MOON et al., "A new class of COX-2 inhibitor, rutaecarpine from <i>Evodia rutaecarpa</i> ", Inflamm. Res., 1999, Vol. 48, pp. 621-625.
75	REDDY et al., "Selective Inhibition of Cyclooxygenase-2 by C-Phycocyanin, a Biliprotein from <i>Spirulina platensis</i> ", Biochem. Biophys. Res. Commun, 2000, Vol. 277, No. 3.
76	LIU et al., "Inhibitory Effects of <i>Angelica pubescens f. biserrata</i> on 5-Lipoxygenase and Cyclooxygenase", Planta Med., 1998, pp. 525-529, Vo. 64.
77	NEWMARK et al. (2000) Beyond Aspirin: Nature's Answer to Arthritis, Cancer, and Alzheimer's Disease. Hohm Press, Prescott, AZ. (Table of Contents only).
78	LAVALLE, James B. (2001) The COX-2 Connection: Natural Breakthrough Treatments for Arthritis, Alzheimer's, and Cancer. Healing Arts Press. (Table of Contents only).
79	TYLER, Varro E., "Phytomedicines: Back to the Future.", J. Nat. Prod., 1999, pp. 1589-1592.
80	MICALUART et al, "Inhibitory Effects of Caffeic Acid Phenethyl Ester on the Activity and Expression of Cyclooxygenase-2 in Human Oral Epithelial Cells and in a Rat Model of Inflammation", Cancer Res. 1999, Vol. 59, pp. 2347-2352.
81	SUBBARAMAIAH et al., " Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells", Cancer Res. 2000, Vol. 60, pp. 2399-2404.
82	SUBBARAMAIAH et al, "Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells", Ann. N.Y. Acad. Sci., 1999, Vol. 889, pp. 214-223.
83	SUBBARAMAIAH et al., "Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells", 1998, J. Biol. Chem. 273(34):21875-21882.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

APR 22 2002

PTO/SB/08A		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/022,862	
		Filing Date	12-13-2001	
		Confirmation Number	4101	
		First Named Inventor	M. Obukowicz	
		Group Art Unit	1614	
Sheet	8	9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

84	WILLIAMS et al. "The flavonoids of <i>Tanacetum parthenium</i> and <i>T. vulgare</i> and their anti-inflammatory properties." <i>Phytochemistry</i> 1999, pp. 417-423, Vol. 51, No. 3.
85	REDDY et al., "Studies on Anti-Inflammatory Activity of Spice Principles and Dietary n-3 Polyunsaturated Fatty Acids on Carrageenan-Induced Inflammation in Rats", <i>Ann. Nutr. Metab.</i> , 1994, pp. 349-358.
86	JUERGENS, U.R., et. al., "The Anti-Inflammatory Activity of L-Menthol Compared to Mint Oil in Human Monocytes In Vitro: A Novel Perspective For Its Therapeutic Use in Inflammatory Diseases", <i>Eur. J. Med. Res.</i> , 1998, pp. 539-545.
87	JUERGENS, U.R., et. al., "Inhibition of Cytokine Production And Arachidonic Acid Metabolism By Eucalyptol (1.8-Cineole) In Human Blood Monocytes In Vitro", <i>Eur. J. Med. Res.</i> , 1998, pp. 508-510.
88	HAQQI et al., "Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea", <i>Proc. Natl. Acad. Sci. USA</i> , 1999, pp. 4524-4529, Vol. 96.
89	ALANKO et al., "Modulation of arachidonic acid metabolism by phenols: Relation to their structure and anti-oxidant/pro-oxidant properties." <i>Free Radical Biology and Medicine</i> 1999, pp. 193-201, Vol. 26.
90	ZHANG et. al., "Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells", <i>Carcinogenesis</i> , 1999, Vol. 20, No. 3.
91	LINDSEY et al., "Screening of plants used by Southern African traditional healers in the treatment of dysmenorrhoea for prostaglandin-synthesis inhibitors and uterine relaxing activity." <i>Journal of Ethnopharmacology</i> 1999, pp. 9-14, Vol. 64.
92	JANG et al., "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes." <i>Science</i> 1997, pp. 218-220, Vol. 275.
93	GIERSET et al., "A single Amino Acid Difference Between Cyclooxygenase-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors." <i>The Journal of Biological Chemistry</i> , 1996, pp. 15810-15814, Vol. 271, No. 26.
94	Nexrutine brochure for Remedief, "Triple Action Pain Management with Natural Cox-2 Inhibitor." Undated
95	Hawley's Condensed Chemical Dictionary, 13th Edition, Revised by Lewis, 1997, page 736.
Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/022,862
				Filing Date	12-13-2001
				Confirmation Number	4101
				First Named Inventor	M. Obukowicz
				Group Art Unit	1614
Sheet	9	9	9	Attorney Docket No.	3475/1A/US (PHA 4140.7)

	96	J. Heterocyclic Chem. 1982, pp. 193-200, Vol. 19, No. 1.	
--	----	--	--

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.